Results of surgical treatment of non–small cell lung cancer: validation of the new postoperative pathologic tnm classification

Jassem, Jacek; Skokowski, Jan; Dziadziuszko, Rafał; Jassem, Ewa; Szymanowska, Amelia; Rzyman, Witold; Roszkiewicz, A

doi:10.1067/mtc.2000.105825

Cited by 61 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 1997 system has been reported to have no significant difference between stages IB and IIA in many reports. [16][17][18][19][20][21][22] The 5-year survival rate of patients with stage IB disease is inferior to that of patients with stage IIA disease in our series according to the 1997 system. Prognosis in stage IIA has not been evaluated properly because of small number of the patients.…”

Section: Discussionmentioning

confidence: 72%

“…Prognosis in stage IIA has not been evaluated properly because of small number of the patients. [16][17][18][19][20][21][22] The proportion of patients with stage IIA disease in our series increases from 2.5% to 9.5% in the 2009 system, and the 5-year survival rate of patients with stage IB disease is slightly superior to that of patients with stage IIA disease, but there is no difference between stages IB and IIA. Similar results are reported in another report.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Unification of T2a and T2b Tumors to T2 Tumors in Non-Small Cell Lung Cancer Staging

Haraguchi

Koizumi

Akiyama

et al. 2011

ATCS

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 83%

Unification of T2a and T2b Tumors to T2 Tumors in Non-Small Cell Lung Cancer Staging

Haraguchi

Koizumi

Akiyama

et al. 2011

ATCS

View full text Add to dashboard Cite

“…No câncer de pulmão de células não pequenas estádio I, a sobrevida em cinco anos é de 70 a 80%, (22) enquanto que nos está-dios mais avançados (III e IV) a mortalidade no mesmo período é superior a 90%. (23,24) O presente estudo evidenciou que o acesso ao hospital para investigação dos sintomas relacionados ao câncer de pulmão é, em geral, demorado. Procuraram assistên-cia médica após 60 dias do início dos sintomas 58% dos pacientes.…”

Section: Discussionunclassified

Retardo no diagnóstico e no tratamento cirúrgico do câncer de pulmão

Knorst¹,

Dienstmann²,

Fagundes³

2003

J. Pneumologia

View full text Add to dashboard Cite

Introdução: O câncer de pulmão é a principal causa de morte relacionada a câncer no mundo.Objetivo: Determinar o tempo despendido com o diagnóstico, o estadiamento e o tratamento cirúrgico do cân-cer de pulmão em um hospital universitário.Método: Entre janeiro de 1990 e dezembro de 1998, 69 pacientes receberam diagnóstico de câncer de pulmão e foram tratados com cirurgia no Hospital das Clíni-cas de Porto Alegre. Os prontuários destes pacientes (53 homens e 16 mulheres) foram revisados, sendo coletados dados clínicos, histológicos, datas de consultas ambulatoriais, de internação hospitalar, de exames e de procedimentos, assim como o local de investigação.Resultados: Quinze pacientes foram investigados em ambulatório (grupo I), 28 em ambulatório e durante internação (grupo II) e 26 durante internação (grupo III). A idade dos pacientes variou entre 43 e 79 anos (média de 61 ± 10 anos). Quarenta e três pacientes eram tabagistas atuais e 23 ex-tabagistas. O tempo médio do aparecimento dos sintomas até a primeira consulta foi de 110 dias e da primeira consulta até o diagnóstico foi de 33 dias. Vinte e cinco dias transcorreram entre o diagnóstico e a cirurgia. A média de tempo da primeira consulta até a cirurgia (tempo total) foi de 58 dias. A média do tempo total foi de 72 dias no grupo I, 72 dias no grupo II e 35 dias no grupo III (p < 0,01). Não houve diferença significativa no tempo total, considerando-se os diferentes está-dios da doença (p = 0,16). Conclusões:Os resultados mostraram retardo na procura de atendimento médico e retardo adicional no tratamento do câncer de pulmão em pacientes cuja investigação foi ambulatorial. (J Pneumol 2003;29(6):358-64) Descritores -Neoplasias pulmonares/cirurgia. Avanços da doença.Background: Lung cancer is the leading cause of cancer-related death worldwide.Objective: To determine the time spent diagnosing, staging and surgically treating lung cancer in a university hospital. Method:Between January 1990 and December 1998, 69 (53 male, 16 female) patients were diagnosed with lung cancer and underwent surgery. The hospital records of these patients were reviewed to evaluate clinical and histological data, dates of outpatient visits, hospital admission, tests and procedures, as well as to determine if the patients were examined as inpatients or as outpatients. Results:The 15 patients investigated as outpatients were designated as group I, the 28 examined as both inpatients and outpatients as group II, and the 26 investigated as inpatients as group III. Age ranged from 43 to 79 years (mean ± SD; 61 ± 10). Of the 69 patients, 43 were smokers and 23 were ex-smokers. The mean time from onset of symptoms to the first outpatient visit was 110 days and 33 days from the first outpatient visit until diagnosis. There was a lapse of 25 days between diagnosis and surgery. The mean total elapsed time between the first outpatient visit and surgery was 58 days. The mean total time was 72 days for group I, 72 days for group II, and 35 days for group III (p < 0.01). There was no significant di...

show abstract

“…Surgical treatment is generally considered curative for early-stage NSCLC. However, more than 60% patients suffer local or distant recurrence of NSCLC at early time after curative resection (Jassem et al, 2000). Platinum-based adjuvant chemotherapy is mostly used for these patients.…”

Section: Introductionmentioning

confidence: 99%

Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy

Xie

He²,

Sun³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To evaluate the prognostic value of the expression of excision repair cross-complementation group l (ERCC1), MutS protein homolog 2 (MSH2) and poly ADP-ribose polymerase 1 (PARP1) in non-small-cell lung cancer patients receiving platinum-based postoperative adjuvant chemotherapy. Methods: Immunohistochemistry was applied to detect the expression of ERCC1, MSH2 and PARP1 in 111 cases of non-small cell lung cancer paraffin embedded surgical specimens. Through og-rank survival analysis, we evaluated the prognostic value of the ERCC1, MSH2, PARP1 and the related clinicopathological factors. COX regression analysis was used to determine whether ERCC1, MSH2 and PARP1 were independent prognostic factors. Results: In the enrolled 111 non-small cell lung cancer patients, the positive expression rate of ERCC1, MSH2 and RARP1 was 33.3%, 36.9% and 55.9%, respectively. ERCC1 (P<0.001) and PARP1 (P=0.033) were found to be correlated with the survival time while there was no correlation for MSH2 (P=0.298). Patients with both ERCC1 and PARP1 negative cancer had significantly longer survival time than those with ERCC1 (P=0.042) or PARP1 (P=0.027) positive alone. Similalry, the survival time of patients with both ERCC1 and PARP1 positive cancer was shorter than those with ERCC1 (P=0.048) or PARP1 (P=0.01) positive alone. Conclusion: Patients with ERCC1 or PARP1 negative non-small cell lung cancer appear to benefit from platinum-based postoperative adjuvant chemotherapy.

show abstract

Results of surgical treatment of non–small cell lung cancer: validation of the new postoperative pathologic tnm classification

Abstract: Most of our findings confirmed prognostic relevance of the current pTNM stage grouping in patients with resectable non-small cell lung cancer. However, despite recent modifications, there is still a significant heterogeneity that flaws stage IIIA.

Cited by 61 publications

References 12 publications

Unification of T2a and T2b Tumors to T2 Tumors in Non-Small Cell Lung Cancer Staging

Unification of T2a and T2b Tumors to T2 Tumors in Non-Small Cell Lung Cancer Staging

Retardo no diagnóstico e no tratamento cirúrgico do câncer de pulmão

Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy

Contact Info

Product

Resources

About